SCHEMBL4865287

SCHEMBL4865287

COc1cc(C2=NNC(=O)C2=NNc2ccc(C)c(-c3cc(OC)c(OC)c(OC)c3)c2)cc(OC)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.39
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
GFER P55789 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDR P35968 1/20 0.35
FLT3 P36888 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
TUBB4A P04350 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865283 1.00 BRD4 (0.39) BRD4ALDH1A1LMNAKDM4EMEN1
SCHEMBL4863304 0.93 BRD4 (0.36) BRD4ALDH1A1LMNAKDM4EMEN1
SCHEMBL4863327 0.93 BRD4 (0.36) BRD4ALDH1A1LMNAKDM4EMEN1
SCHEMBL4859138 0.92 PDGFRB (0.39) BRD4ALDH1A1LMNAKDM4EMEN1
SCHEMBL4859141 0.92 PDGFRB (0.39) BRD4ALDH1A1LMNAKDM4EMEN1
SCHEMBL4864178 0.90 EGFR (0.43) BRD4ALDH1A1KDM4EMAPK1HTT
SCHEMBL4855994 0.90 FYN (0.42) BRD4ALDH1A1MAPTKDRFLT3
SCHEMBL4862410 0.90 MAPT (0.38) ALDH1A1MEN1NPC1GAAMAPT
SCHEMBL4864163 0.90 EGFR (0.43) BRD4ALDH1A1KDM4EMAPK1HTT
SCHEMBL4855988 0.90 FYN (0.42) BRD4ALDH1A1MAPTKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A BRD4 1432/4885ALDH1A1 3536/4885LMNA 828/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A BRD4 1432/4885ALDH1A1 3536/4885LMNA 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.